Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0020538 (
hypertension
)
170,190
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The energy demands of the heart are normally met by oxidation of both glucose and fatty acids. Fatty acid oxidation is limited by the uptake of fatty acyl coenzyme A (CoA) into the mitochondria, a process regulated by carnitine palmitoyltransferase (CPT)1. Malonyl CoA is a potent endogenous inhibitor of CPT1, and therefore plays an integral role in the control of myocardial fatty acid oxidation.
Malonyl-CoA decarboxylase
(
MCD
) is responsible for the removal of malonyl CoA and may control myocardial fatty acid oxidation. Indeed, strategies using
MCD
inhibitors and
MCD
knockout mice have provided the first evidence for a direct role of
MCD
in the control of myocardial fatty acid oxidation. Based on these studies, pharmacologic inhibition of
MCD
has been proposed to be a viable approach for the treatment of ischemic heart disease resulting from a variety of pathologic conditions, including coronary artery diseases, pathologic hypertrophy, and
hypertension
.
...
PMID:Malonyl-CoA decarboxylase is a major regulator of myocardial fatty acid oxidation. 1638 95